A prospective Crossover Triple-blind Controlled Trial on the Safety and Efficacy of Iranian Recombinant FVIII (Safacto) versus Plasma Derived FVIII A pilot study

نویسندگان
Eshghi , P ID 1
Malek , F ID 2
Gorji, F ID 3
Abolghasemi , H ID 4
Naderi , M ID 5
Panahi, Y ID 6
Habibpanah, B ID 7
Fatohlahzadeh, E ID 8

1

2

3

4

5

6

7

8

doi
چکیده

Background: Considering the increasing number of patients with hemophilia and infrastructure requirements for a comprehensive approach, development of a recombinant factor has become a milestone. The objective of this study was to assess the safety, efficacy and non inferiority of Safacto (Recombinant factor VIII) compared with plasma-derived factor in the treatment of hemophilia ...

کلیدواژه‌ها
Hemophilia A, Plasma derived factor VIII, Recombinant factor, Safacto